Hapten Immunetherapy for Liver Cancer HBV+ 40 Years and Restores Normal HBV-
1. Department of Oncology, TaiMei Baofa Cancer Hospital, Dongping 271500, China
2. Department of Oncology, Jinan Baofa Cancer Hospital, Jinan 250000, China
| Abstract: | Chronic hepatitis B virus (HBV) infection has considered a major risk factor for the development and progression of hepatocellular carcinoma (HCC), long-term lack of effective treatment worldwide. Hapten enhanced intratumoral chemotherap may provide a revival effect of immune system to against cancer cell of HCC and HBV. Methods. Single-cell RNA sequencing (scRNA-seq) was used to analyze the changes at the molecular level of tumor reflection from the untreated tumor after HEIC treated a few multi-focal HCC tumors. Results. After treatment with major tumors, both BMEM and Naive B cells, significantly increased MHC II signaling pathway-related genes, while plasma cells upregulated MHC I-related genes. Fibroblast, γδT/NK cells and Neutrophils, while NKT cells, Plasma cells, Endothelial cells, and B cells and M2 Macrophage showed values of AUC less than 0.6 which indicated minor affection or possible minor contribution to the therapeutic effect. It was observed significantly reduced scores of HBV-infection pathways, the percentages of CSTA+DCs and Kupffer cells were reduced, showing accordance with the attenuated HBV caused inflammation. Patient of HCC HBV DNA titter drop to zero and got control of the multifocal masses of HCC who still live. It is first discovered hapten is modifiing neo HBsAg (HBsAg) while it is modifying the TAAs’s epitope, which return to a neo HBsAg, neu TAAs and rejuvenate a revival effects of immune system against cancer and HBV, i.e., by activating efficacy of CD4 T-cell activation and CD8 T-cell responses, thus, prolonging the survival time of patients, and maintaining the quality of life. Conclusions. This study provides new biological knowledge of therapy, hapten based intratumoral chemoimmunotherapy is playing an important role to improve neu TAAs and neo HBsAg for a revival of immune effect to control cancer cell and HBV in HCC with HBV positive. |
| Keywords: | Immunotherapy; SscRNA-seq; Liver Cacner with HBV; HBV Vaccine; HBsAg-based Immune Therapy |
| DOI: | 10.57237/j.wjcm.2026.01.002 |
View:
Downloads:
Received: 9 March 2026
Accepted: 15 April 2026
Published Online: 27 April 2026
References
| [1] | Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chinese medical journal. 2022; 135(05): 584-90. https://doi.org/10.1097/CM9.0000000000002108 |
| [2] | Liang-Qing Dong 1, Li-Hua Peng 2, Li-Jie Ma, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020 May; 72(5): 896-908. https://doi.org/10.1016/j.jhep.2019.12.014 |
| [3] | L Jia, Y Gao, Y He, et al. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020 Sep: 159: 104992. https://doi.org/10.1016/j.phrs.2020.104992 |
| [4] | Liu C-Y, Chen K-F, Chen P-J. Treatment of liver cancer. Cold Spring Harbor perspectives in medicine. 2015; 5(9): a021535. https://doi.org/10.1101/cshperspect.a021535 |
| [5] | Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. Journal of Experimental & Clinical Cancer Research. 2018; 37(1): 1-12. https://doi.org/10.1186/s13046-018-0777-4 |
| [6] | Yu B, Lu Y, Gao F, Jing P, Wei H, Zhang P, et al. Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy. Lung Cancer: Targets and Therapy. 2015: 1-11. https://doi.org/10.2147/LCTT.S70679.eCollection 2015 |
| [7] | Gao F, Jing P, Liu J, Lu Y, Zhang P, Han W, et al. Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy. Journal of Hepatocellular Carcinoma. 2015: 57-68. https://doi.org/10.2147/JHC.S80756.eCollection 2015 |
| [8] | The Professional Committee of Integrated Diagnosis and Treatment of the Chinese Anti-Cancer Association, the Research Center of the National Association of Radiological and Therapeutic Clinical Medicine and the National Interventional Medicine Innovation Alliance. Clinical Practice Guidelines for Interventional Therapy for Advanced Pancreatic Cancer (Trial) (7th edition) Journal of Clinical Radiology 43 (10), 2024. |
| [9] | Sakamoto, E., et al. Chemical- and Drug-Induced Allergic, Inflammatory, and Autoimmune Diseases Via Haptenation. Biology (Basel) 12(2023). |
| [10] | Yu, B., et al. Awaken Immune Cells by Hapten Enhanced Intratumoral Chemotherapy with Penicillin Prolong Pancreatic Cancer Survival. J Cancer 14, 1282-1292 (2023). https://doi.org/10.7150/jca.82985.eCollection 2023 |
| [11] | Lu, Y. & Low, P. S. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 51, 153-162 (2002). https://doi.org/10.1007/s00262-002-0266-6 |
| [12] | Erkes, D. A. & Selvan, S. R. Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. J Immunol Res 2014, 175265 (2014). https://doi.org/10.1155/2014/175265 |
| [13] | Schrand, B., et al. Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity. Nature Communications 9, 3348 (2018). https://doi.org/10.1038/s41467-018-05566-x |
| [14] | Yu, B., et al. Successful targeting in situ of an oncogenic nuclear antigen by hapten induced tumor associated autoantibodies (iTAA). Sci Rep 13, 9902 (2023). https://doi.org/10.1038/s41598-023-36757-2 |
| [15] | Yu, B., et al: Hapten enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy. Journal of Hepatocellular carcinoma, 2015: 2 57-78. https://doi.org/10.2147/JHC.S80756.eCollection 2015 |
| [16] | Yu, B., et al. Cancer new treatment series: Comparison immune changes of HCC by scRNA-Seq following HELC treatment one case study. Trends in Immunotherapy 2024, 8(2), 8937. https://doi.org/10.24294/ti.v8.i2.8937 |
| [17] | Ziegenhain C, Vieth B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, et al. Comparative analysis of single-cell RNA sequencing methods. Molecular cell. 2017; 65(4): 631-43. e4. https://doi.org/10.1016/j.molcel.2017.01.023 |
| [18] | Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, et al. Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer cell. 2019; 36(4): 418-30. e6. https://doi.org/10.1016/j.ccell.2019.08.007 |
| [19] | Giannini A, et al. Outcomes of high-grade cervical dysplasia with positive margins and HPV persistence after cervical conization. Vaccines (Basel). (2023) 11(3): 698. https://doi.org/10.3390/vaccines11030698 |
| [20] | Tran LS, et al. Interleukin-17A promotes arginase-1 production and 2,4-dinitrochlorobenzene-induced acute hyperinflammation in human papillomavirus E7 oncoprotein-expressing skin. J Innate Immun (2015) 7(4): 392–404. https://doi.org/10.1159/000374115 |
| [21] | Liu X, et al. Chemical immune conization of precancerous cervical lesions awakens immune cells and restores normal HPV negative and abnormal proliferation. Frontiers in Immunology. 2024 (03) 1. https://doi.org/10.3389/fimmu.2023.1259723 |
| [22] | Wei, X., et al., Elevated enteric putrescine suppresses differentiation of intestinal germinal center B cells. Int Immunopharmacol, 2024. 128: p. 111544. https://doi.org/10.1016/j.intimp.2024.111544 |
| [23] | Shi, S., et al., CXCR6 defines therapeutic subtypes of CD4+ cytotoxic T cell lineage for adoptive cell transfer therapy in pediatric B cell acute lymphoblastic leukemia. International Immunopharmacology, 2024. 132. https://doi.org/10.1016/j.intimp.2024.111972 |
| [24] | Chen, S., et al., fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018. 34(17): p. i884-i890. https://doi.org/10.1093/bioinformatics/bty560 |
| [25] | Hao, Y., et al., Integrated analysis of multimodal single-cell data. Cell, 2021. 184(13): p. 3573-3587.e29. https://doi.org/10.1016/j.cell.2021.04.048 |
| [26] | McGinnis, C. S., L. M. Murrow, and Z. J. Gartner, DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst, 2019. 8(4): p. 329-337.e4. https://doi.org/10.1016/j.cels.2019.03.003 |
| [27] | Subramanian, A., et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A, 2005. 102(43): p. 15545-50. https://doi.org/10.1073/pnas.0506580102 |
| [28] | Wu, T., et al., clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The Innovation, 2021. 2(3): p. 100141. https://doi.org/10.1016/j.xinn.2021.100141 |
| [29] | Skinnider, M. A., et al., Cell type prioritization in single-cell data. Nat Biotechnol, 2021. 39(1): p. 30-34. https://doi.org/10.1038/s41587-020-0605-1 |
| [30] | Chu, Y., et al., Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med, 2023. 29(6): p. 1550-1562. https://doi.org/10.1038/s41591-023-02371-y |
| [31] | Tang, F., et al., A pan-cancer single-cell panorama of human natural killer cells. Cell, 2023. 186(19): p. 4235-4251.e20. https://doi.org/10.1016/j.cell.2023.07.034 |
| [32] | Cao, J., et al., The single-cell transcriptional landscape of mammalian organogenesis. Nature, 2019. 566(7745): p. 496-502. https://doi.org/10.1038/s41586-019-0969-x |
| [33] | Gulati, G. S., et al., Single-cell transcriptional diversity is a hallmark of developmental potential. Science, 2020. 367(6476): p. 405-411. https://doi.org/10.1126/science.aax0249 |
| [34] | Zhang, Y., et al., CellCall: integrating paired ligand–receptor and transcription factor activities for cell–cell communication. Nucleic Acids Research, 2021. 49(15): p. 8520-8534. https://doi.org/10.1093/nar/gkab638 |
| [35] | Burberry, A., et al., C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature, 2020. 582(7810): p. 89-94. https://doi.org/10.1038/s41586-020-2288-7 |
| [36] | Cicardi, M. E. and D. Trotti, C9orf72 role in myeloid cells: new perspectives in the investigation of the neuro-immune crosstalk in amyotrophic lateral sclerosis and frontotemporal dementia. Ann Transl Med, 2024. 12(6): p. 120. https://doi.org/10.21037/atm-24-86 |
| [37] | Li, Q., et al., Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure. BMC Gastroenterol, 2020. 20(1): p. 106. https://doi.org/10.1186/s12876-020-01258-3 |
| [38] | Zhu, C., et al., Hepatitis B virus inhibits the expression of complement C3 and C4, in vitro and in vivo. Oncol Lett, 2018. 15(5): p. 7459-7463. https://doi.org/10.3892/ol.2018.8223 |
| [39] | Ye, B., et al., T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death & Disease, 2015. 6(3): p. e1694-e1694. https://doi.org/10.1038/cddis.2015.42 |
| [40] | Adams, N. M., et al., Transcription Factor IRF8 Orchestrates the Adaptive Natural Killer Cell Response. Immunity, 2018. 48(6): p. 1172-1182.e6. https://doi.org/10.1016/j.immuni.2018.04.018 |
| [41] | HBV-Specific T(rm) Cells Correlate with Relapse-Free Survival in HCC. Cancer Discov. 2021 Sep; 11(9): OF6. https://doi.org/10.1158/2159-8290.CD-RW2021-103 |
| [42] | He, X., Tang R., Lou J., et al. Pseudo-trajectory inference for identifying essential regulations and molecules in cell fate decisions. J Biol Phys. 2024 Nov 14; 51(1): 2. https://doi.org/10.1007/s10867-024-09665-3 |
| [43] | Mahmood F., Xu R., Awan M U N., et al. HBV Vaccines: Advances and Development. Vaccines (Basel). 2023 Dec 18; 11(12): 1862. https://doi.org/10.3390/vaccines11121862 |
| [44] | Su J, Brunner L., Edanur Ates Oz E. A., et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models. J Hepatol. 2023 Apr; 78(4): 717-730. https://doi.org/10.1016/j.jhep.2022.12.013 |
| [45] | Akbar S. M. F., Al-Mahtab M., Uddin M. H., et al. HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection. Hepatobiliary Pancreat Dis Int. 2013 Aug; 12(4): 363-9. https://doi.org/10.1016/s1499-3872(13)60057-0 |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us